Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (5362)	9/21/1998 5:01:00 PM
From: Robert L. Ray	of 6136

AGPH made a Bloomberg market mover list today. home.snap.com Agouron Pharmaceuticals Inc. (AGPH) rose as much as 3 3/4 to 35 1/4 as the developer of drugs to treat HIV was raised to ''buy'' from ''outperform'' by Lehman Brothers Inc. Eric Ende, who co-authored a report with analyst C. Anthony Butler. They raised their earnings estimate for fiscal 1999 ending in June to $1.33 a share from 94 cents, reflecting quicker penetration and greater market share for Agouron's AIDS drug Viracept. Ende said Agouron will benefit from last week's news that Merck & Co. (MRK) stopped the twice-daily dosage trials for its AIDS drug Crixivan, and from Abbott Laboratories (ABT)'s manufacturing problems with its Norvir.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next